Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 February 1987:
Vol. 235. no. 4791, pp. 895 - 898
DOI: 10.1126/science.3580039
Prev | Table of Contents | Next

Articles

Science, Vol 235, Issue 4791, 895-898
Copyright © 1987 by American Association for the Advancement of Science

articles

Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo

JW Greiner, F Guadagni, P Noguchi, S Pestka, D Colcher, PB Fisher, and J Schlom

Heterogeneity in the expression of tumor-associated antigens, as defined by the binding of monoclonal antibodies, is a characteristic common to most, if not all, human carcinoma cell populations. Antigen-negative cells within the population can escape detection and therapy by their failure to bind the appropriate antibody. Therefore, the extent of antigenic heterogeneity is an important consideration when designing protocols for the management of cancer by administration of monoclonal antibodies. One approach to counteracting the effect of antigenic heterogeneity is the use of clone A of recombinant human leukocyte interferon (Hu-IFN-alpha A). Administration of Hu-IFN-alpha A in vivo effectively increased the amount of tumor antigen expressed by a human colon xenograft in situ and augmented the localization of a radiolabeled monoclonal antibody to the tumor site. Concomitant administration of Hu-IFN-alpha A and monoclonal antibody may thus be effective in overcoming the antigenic heterogeneity of carcinoma cell populations and in enhancing the efficacy of monoclonal antibodies in the detection and treatment of carcinoma lesions.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Interferons: 50 Years after Their Discovery, There Is Much More to Learn.
S. Pestka (2007)
J. Biol. Chem. 282, 20047-20051
   Abstract »    Full Text »    PDF »
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies.
R. M. Sharkey and D. M. Goldenberg (2005)
J. Nucl. Med. 46, 115S-127S
   Abstract »    Full Text »    PDF »
T-bet Regulates Metastasis Rate in a Murine Model of Primary Prostate Cancer.
S. L. Peng, M. J. Townsend, J. L. Hecht, I. A. White, and L. H. Glimcher (2004)
Cancer Res. 64, 452-455
   Abstract »    Full Text »    PDF »
Interferon-kappa , a Novel Type I Interferon Expressed in Human Keratinocytes.
D. W. LaFleur, B. Nardelli, T. Tsareva, D. Mather, P. Feng, M. Semenuk, K. Taylor, M. Buergin, D. Chinchilla, V. Roshke, et al. (2001)
J. Biol. Chem. 276, 39765-39771
   Abstract »    Full Text »    PDF »
Innovations in Monoclonal Antibody Tumor Targeting: Diagnostic and Therapeutic Implications.
J. Schlom (1989)
JAMA 261, 744-746
   Abstract »    PDF »
Inositol Hexakisphosphate Kinase 2 Mediates Growth Suppressive and Apoptotic Effects of Interferon-beta in Ovarian Carcinoma Cells.
B. H. Morrison, J. A. Bauer, D. V. Kalvakolanu, and D. J. Lindner (2001)
J. Biol. Chem. 276, 24965-24970
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)